Usage of Deoxyspergualin on Steroid-Resistant Acute Rejection in Living Donor Liver Transplantation

Kawagishi, Naoki; Satoh, Kazushige; Enomoto, Yoshiharu; Akamatsu, Yorihiro; Sekiguchi, Satoshi; Satoh, Susumu

doi:10.1620/tjem.208.225

Cited by 8 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Groth et al (1990) reported the reversal of liver graft rejection with DSG in a patient in whom previous treatment with steroids and OKT3 had failed. We previously reported that DSG was effective for SRR in 6 out of 8 living donor liver transplantation recipients without inducing any severe adverse effects (Kawagishi et al 2006). This is our seventh patient, in whom DSG was effective for the treatment of SRR in liver transplantation.…”

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

Steroid-Resistant Late Acute Rejection after a Living Donor Liver Transplantation: Case Report and Review of the Literature

Nakanishi

Kawagishi

Sekiguchi

et al. 2007

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 66%

“…In liver transplantation, Groth et al (1990) reported the reversal of acute rejection with DSG in a patient in whom previous treatments with steroids and anti-CD3 murine monoclonal antibody (OKT-3) had failed. We used DSG, which showed a good efficacy and safety in patients with steroid-resistant rejection, after liver transplantation (Kawagishi et al 2006).…”

mentioning

confidence: 99%

Steroid-Resistant Late Acute Rejection after a Living Donor Liver Transplantation: Case Report and Review of the Literature

Nakanishi

Kawagishi

Sekiguchi

et al. 2007

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

“…In our institution, we have experienced 11 ABO-I cases out of 96 LDLTs until now (Kawagishi et al 2006). It was reported that the complications of ABO-I LT, including Ab-mediated hyperacute rejection, hepatic necrosis and intrahepatic biliary complications were closely related to perioperative anti-A or anti-B Ab titer (Rydberg 2001;Egawa et al 2004).…”

Section: Discussionmentioning

confidence: 99%

“…Splenectomy was not routinely performed for pediatric patients. Rejection was treated with steroid pulse therapy, steroid recycling or deoxyspergualin (DSG) (Kawagishi et al 2006).…”

Section: Immunosuppressive Therapymentioning

confidence: 99%

Development of a Novel ELISA for Detection of Anti-A and Anti-B Antibodies in Recipients of ABO-Incompatible Living Donor Liver Grafts

Satoh

Kawagishi

Minegishi

et al. 2007

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

The survival rate in ABO-incompatible (ABO-I) liver transplantation was much lower than that in ABO-compatible recipients for the early experiences. It is therefore essential to develop the precise and fast measurement of anti-A and anti-B antibodies (Abs) to prevent humoral rejection in ABO-I liver transplantation. Agglutination titer has been the standard method to measure these Abs, but the interpretation of the results is subject to bias. Here, we have developed an objective and quantitative enzyme-linked immunosorbent assay (ELISA) to measure anti-A and anti-B Abs. This test requires only a small amount (10 μ l) of recipient's serum. We applied the newly developed ELISA to monitor living donor liver transplant recipients and investigated the correlation between ELISA and agglutination titer. The Spearman's correlation coefficient for Abs ranged from 0.461 to 0.812. Moreover, in one case of humoral rejection, the increase of Abs was detected by ELISA one day earlier than by the agglutination titer. In conclusion, our ELISA method proved useful to detect an increase of anti-A and anti-B Abs titers at an early stage, thereby contributing to a prompt treatment of humoral rejection due to ABO-I.ABO-incompatibility; ELISA; living donor liver transplantation; ABO histo-blood group antibodies; rejection

show abstract

“…At doses of 3–5 mg given for 10–14 days, 76% of early episodes responded, increasing to 87.5% with concurrent methylprednisolone (123). In small series, it has also shown 55% efficacy in treating nine liver transplant recipients with steroid non‐responsive rejection (124) and, with plasmapheresis, for successfully treating 80% of cases of acute humoral renal rejection (125).…”

Section: Srl and Erlmentioning

confidence: 99%

Immunosuppression in pediatric solid organ transplantation: Opportunities, risks, and management

Tredger¹,

Brown²,

Dhawan

2006

Pediatric Transplantation

View full text Add to dashboard Cite

The pediatric transplant community stands at a time of unprecedented choice of immunosuppressive agents - and with a legacy of morbidity from those agents used in the previous two decades. This review considers the clinical utility and side-effect profiles of immunosuppressants used widely in current practice (e.g., glucocorticoids, azathioprine, ciclosporin, tacrolimus, mycophenolate, and sirolimus) and those agents which are in increasing use or in evaluation (e.g., IL-2 receptor antibodies, everolimus, FTY720, LEA29Y, and deoxyspergualin). Further consideration is given to the wider drug interactions likely during the use of new immunosuppressant regimens and to our growing awareness of the influences of genetic heterogeneity on drug efficacy and handling. Finally, we consider the new demands being placed on the use of drug monitoring to regulate dosage of this new repertoire of immunosuppressants.

show abstract

Usage of Deoxyspergualin on Steroid-Resistant Acute Rejection in Living Donor Liver Transplantation

Cited by 8 publications

References 20 publications

Steroid-Resistant Late Acute Rejection after a Living Donor Liver Transplantation: Case Report and Review of the Literature

Steroid-Resistant Late Acute Rejection after a Living Donor Liver Transplantation: Case Report and Review of the Literature

Development of a Novel ELISA for Detection of Anti-A and Anti-B Antibodies in Recipients of ABO-Incompatible Living Donor Liver Grafts

Immunosuppression in pediatric solid organ transplantation: Opportunities, risks, and management

Contact Info

Product

Resources

About